Aβ Metallobiology and the Development of Novel Metal-Protein Attenuating Compounds (MPACs) for Alzheimers Disease

Author(s): Cyril C. Curtain, Kevin J. Barnham, Ashley I. Bush

Journal Name: Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents
Continued as Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry

Volume 3 , Issue 4 , 2003


Over a decade of studies have pointed to metal mediated neural oxidative damage as an attractive target for the treatment of Alzheimers disease. Because of the nature of the blood brain barrier, systemic depletion of the metals, copper, zinc and possibly iron, is not a viable approach. However preliminary studies with CQ, a blood brain barrier penetrating chelating agent, are showing promise. CQ probably works by combining with the metal centres, primarily copper and zinc complexes of Aβ, in the neuropil. This review discusses some of the background that resulted in CQ becoming a lead compound and how we might advance our understanding of its action

Keywords: Alzheimer, oxidative, zinc

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [309 - 315]
Pages: 7
DOI: 10.2174/1568013033483276
Price: $58

Article Metrics

PDF: 1